The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD
Abstract
OBJECTIVE: Bile acids are regulators of lipid and glucose metabolism, and modulate inflammation in the liver and other tissues. Primary bile acids such as cholic acid and chenodeoxycholic acid (CDCA) are produced in the liver, and converted into secondary bile acids such as deoxycholic acid (DCA) and lithocholic acid by gut microbiota. Here we investigated the possible roles of bile acids in non-alcoholic fatty liver disease (NAFLD) pathogenesis and the impact of the gut microbiome on bile acid signalling in NAFLD. DESIGN: Serum bile acid levels and fibroblast growth factor 19 (FGF19), liver gene expression profiles and gut microbiome compositions were determined in patients with NAFLD, high-fat diet-fed rats and their controls. RESULTS: -taurocholate cotransporting polypeptide and paraoxonase 1, no change in mRNA expression for small heterodimer partner and bile salt export pump, and reduced serum FGF19 were evidence of impaired FXR and fibroblast growth factor receptor 4 (FGFR4)-mediated signalling in NAFLD. Taurine and glycine metabolising bacteria were increased in the gut of patients with NAFLD, reflecting increased secondary bile acid production. Similar changes in liver gene expression and the gut microbiome were observed in high-fat diet-fed rats. CONCLUSIONS: The serum bile acid profile, the hepatic gene expression pattern and the gut microbiome composition consistently support an elevated bile acid production in NAFLD. The increased proportion of FXR antagonistic bile acid explains, at least in part, the suppression of hepatic FXR-mediated and FGFR4-mediated signalling. Our study suggests that future NAFLD intervention may target the components of FXR signalling, including the bile acid converting gut microbiome.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Jiao et al. (2018) found that MAFLD patients present elevated primary and secondary bile acids, among which the proportion of DCA is increased and CDCA is decreased.”
From Akkermansia muciniphila alleviates high‐fat‐diet ‐related metabolic‐associated fatty liver disease by modulating gut microbiota and bile acids (2023) · cites this paper as Jiao et al. (2018)
In the citing paper
“Additionally, hepatic CYP7A1 expression is enhanced.”
From Akkermansia muciniphila alleviates high‐fat‐diet ‐related metabolic‐associated fatty liver disease by modulating gut microbiota and bile acids (2023) · cites this paper as Jiao et al. (2018)
In the citing paper
“With increasing severity of NASH and fibrosis, BA levels tend to increase and the composition of BAs changes”
From Novel therapeutic targets for cholestatic and fatty liver disease (2022) · cites this paper as [91]
In the citing paper
“First, the gut microbiota may affect gastrointestinal transit through its regulation of BA synthesis. The gut microbiota is equipped with enzymes for the production of secondary BAs, which may suppress the FGF19- and FXR-mediated signaling, leading to the induction of CYP7A1 [ 49 , 50 ], and consequently elevated de novo BA synthesis and improved colonic transit.”
From Role of gut microbiota in functional constipation (2021) · cites this paper as [49]
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences
Langille, M. G. I., Zaneveld, J., Caporaso, J. G., McDonald, D., Knights, D., Reyes, J. A., Clemente, J. C., Burkepile, D. E., Vega Thurber, R. L., Knight, R., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2676 · Cited by 9,116
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
Vernon, G. C., Baranova, A. V., & Younossi, Z. M. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04724.x · Cited by 3,116
Bile salt biotransformations by human intestinal bacteria
Ridlon, J. M., Kang, D.-J., & Hylemon, P. B. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r500013-jlr200 · Cited by 2,829
Sayin, S. I., Wahlström, A., Felin, J., Jäntti, S., Marschall, H.-U., Bamberg, K., Angelin, B., Hyötyläinen, T., Orešič, M., & Bäckhed, F. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.01.003 · Cited by 2,331
Bile Acids: Natural Ligands for an Orphan Nuclear Receptor
Parks, D. J., Blanchard, S. G., Bledsoe, R. K., Chandra, G., Consler, T. G., Kliewer, S. A., Stimmel, J. B., Willson, T. M., Zavacki, A. M., Moore, D. D., et al. (1999) · Science · doi:10.1126/science.284.5418.1365 · Cited by 2,274
TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis
Thomas, C., Gioiello, A., Noriega, L., Strehle, A., Oury, J., Rizzo, G., Macchiarulo, A., Yamamoto, H., Mataki, C., Pruzanski, M., et al. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.08.001 · Cited by 1,885
Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis
Inagaki, T., Choi, M., Moschetta, A., Peng, L., Cummins, C. L., McDonald, J. G., Luo, G., Jones, S. A., Goodwin, B., Richardson, J. A., et al. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.09.001 · Cited by 1,865
Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis
Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819
Research works printed but not linked: 1
- 10.1172/JCI200421025 · DOI
Cited by
Sorted by citations
Items 701–736 of 736
Influence of bile acids metabolism on hepatic immunity in mice
Guinot, V. (2022) · theses.fr (ABES) · doi:10.70675/b69bb11eza30fz4874z9af2za6e31b2d5ad8
Rôle du récepteur Farnesoid X dans le contrôle central de l'homéostasie énergétique
Deckmyn, B. (2022) · theses.fr (ABES) · doi:10.70675/db76bb16z01f4z4f26zaf99za1003045be0c
Wang, S., Hullar, M. A. J., Curtis, K. R., Kwee, S. A., Park, S., Rettenmeier, C. A., Monroe, K. R., Ernst, T. M., Shepard, J., Wilkens, L. R., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.10.717245
“32 MASLD patients exhibit elevated serum levels of bile acids, along with an increase in SBAs, and a higher abundance of bile acid-metabolizing gut bacteria.”
Liu, H., Wang, S., Wang, N., Wang, F., Ren, J., Zhou, Z., Liu, K., Wang, X., Li, Y., Fu, C., et al. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.121639
Wu, Q., Gao, L.-Y., Feng, H., Liu, H.-L., Gao, H., Peng, W., & Li, N. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1797381
Ding, X., Wang, J., Wang, Y., Xu, H., & Liu, Y. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1807162 · Cited by 1
“In the LCA-induced cholestatic mouse model, consecutive 4-day administration of PTH (75 – 300 mg/kg) has been demonstrated to increase the abundance of Lactobacillaceae and Lactobacillus .”
InfluentialLi, B., Zhang, Y., Li, Z., Chen, Z., Guo, Z., Wu, W., Tan, L., Dong, L., Zhang, X., Lyu, X., et al. (2026) · BMC Gastroenterology · doi:10.1186/s12876-026-04842-1
Alteration of bile acid metabolism in mice under thermoneutral conditions
Soma, H., Yoshida, R., & Ishizuka, S. (2026) · Steroids · doi:10.1016/j.steroids.2026.109794
Xu, M., Zhang, J., Sun, B., Huang, M., Pan, Y., Lin, W., Cai, J., Chen, A., & Chen, P. (2026) · Rhizosphere · doi:10.1016/j.rhisph.2026.101383
Liao, L.-W., Gou, X.-T., & Xia, W. (2026) · Current Medical Science · doi:10.1007/s11596-026-00213-9
“In the liver, FXR activation suppresses de novo lipogenesis via sterol-regulatory element-binding protein 1c (SREBP-1c) and stearoyl-CoA desaturase 1 (SCD1) [131, 132] while promoting fatty acid β-oxidation through PPARα [133].”
wang, S., lin, X., Sun, Z., Cui, S., & Fang, X. (2026) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2026.109166
Ren, G., Duan, H., Zou, X., Qu, J., & Wang, H. (2026) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2026.117614
Ren, X., Zhou, S., & Li, Y. (2026) · Healthcare · doi:10.3390/healthcare14121712
“Suppressed hepatic bile acid signaling further exacerbates metabolic dysfunction in NAFLD [47], whereas time-restricted feeding can ameliorate NAFLD through gut microbiota remodeling [48].”
Wu, D., Yang, Q., Ye, J. Y., Chen, X., Wu, X., Qin, L., Yc, L., Tan, D., & He, Y.-Q. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.122310
Zhang, S. Z., Tu, J., Hong, W., Liu, J., Xue, C., & Dong, N. (2026) · Applied and Environmental Microbiology · doi:10.1128/aem.02412-25
“1) (80).”
Yang, H., Zhang, X., Zhou, D., Zou, J., Xu, L., Chen, M., Zhao, S., Dai, J., Wang, X., Du, X., et al. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118225
Lei, K., Li, J., 韦坤华, Bai, Y., Mao, J., & Su, Z. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1852189
“Clinical studies have shown that patients with MAFLD exhibit significant bile acid metabolic disorders, including elevated total bile acid levels, altered proportions of secondary bile acids, and impaired FXR signaling (28, 29).”
Muniraj, A., Elango, S. V., Iyer, M., Rani, M. R., Vinayagam, S., Gnanasekaran, L., Yadav, M. K., Rao, K. R. S. S., Vellingiri, B., Mukherjee, A. G., et al. (2026) · Comprehensive physiology · doi:10.1002/cph4.70220 · Cited by 1
“Conversely, gut microbiota modifies primary bile acids into secondary bile acids, thereby altering receptor activation profiles and downstream signaling (Jiao et al. 2018; Joyce and Gahan 2017).”
Zheng, H., Li, Y. C., Li, W., Guo, X., Huang, C., Zhou, S., Wang, Z., Chen, C., Hu, L., Hu, L., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-63314-4
“Lactobacillus species play a key role in bile acid metabolism due to their high bile salt hydrolase activity (BSH) 51 , which facilitates the production of secondary bile acids that promote bile acids de novo synthesis 52 .”
Self-citationMetabolic Rewiring in MASLD: From Disease Mechanisms to Precision Medicine
Lonardo, A., & Weiskirchen, R. (2026) · Metabolites · doi:10.3390/metabo16080529
“Bile acid metabolism provides another critical interface between the gut microbiome and hepatic metabolic regulation [128,129].”
Cai, W., Yang, D., Li, H., Zhang, C., Che, H., & Li, H. (2026) · Food Bioscience · doi:10.1016/j.fbio.2026.109728
Liu, J., Zhao, M., Wang, S., Zhang, C., Zhong, Y., & Qu, Y. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1917467
“Patients exhibit elevated serum bile acid levels that correlate with the degree of steatosis, whereas downregulation of FXR further weakens bile acid homeostasis and metabolic regulation, thereby aggravating gut-liver axis dysfunction (Bechmann et al., 2013; Jiao et al., 2018).”
Bi, Y., Song, W., Glymenaki, M., Hu, J., Li, X., Huang, H., Peng, Y., Ni, S., Haonon, O., Liu, Z., et al. (2026) · iMeta · doi:10.1002/imt2.70144 · Cited by 1
Microbial Metabolites and Neural Epigenetic Circuitry in Emotional Homeostasis and Depression
Chen, Y., Gong, X., Chen, Y., Liu, Y., Zhang, X., & Manickam, S. (2026) · Nutrition Reviews · doi:10.1093/nutrit/nuag119
Plant-Derived Exosome-like Nanovesicles for Metabolic Dysfunction-Associated Steatotic Liver Disease
Kuang, T., Wang, L., Shi, Y., Cheng, J., & Pan, S. (2026) · Veterinary Sciences · doi:10.3390/vetsci13090851
“Secondary bile acids, such as deoxycholic acid, can antagonize farnesoid X receptor (FXR) signaling and thereby promote bile acid synthesis [68].”
Gao, W., Shi, J., Xie, L., Xiao, P., Chen, W., Feng, Q., Gan, K.-X., Fu, G., Wu, J., Liu, W., et al. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.122328
Self-citationReichert, M., Strowitzki, M. J., Tuffs, C., Amati, A., Amin, D., Raj, S., Sprenger, T., Hecker, A., & Schneider, M. (2026) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2927-4771
Huai, Q., Li, X., Wang, H., & Yin, S. (2026) · American Journal Of Pathology · doi:10.1016/j.ajpath.2026.09.004
Tang, X., Gasaly, N., Chen, X., Toye, L., & de Vos, P. (2026) · Journal of Functional Foods · doi:10.1016/j.jff.2026.107522
Kotlyarov, S. N., Котлярова, А. А., Catanzaro, R., & Marotta, F. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198614
Interplay Between the Gut Microbiome and Oxidative Stress in Type 2 Diabetes
Kim, J.-W., Lee, Y., Kim, K., & Ko, S.-H. (2026) · Antioxidants · doi:10.3390/antiox15101278
“MASLD is closely linked to T2D through insulin resistance, lipotoxicity, hepatic oxidative stress, and gut–liver-axis alterations involving intestinal permeability, microbial metabolites, bile acid signaling, and endogenous ethanol production [10,69,70].”
Yu, F., Yin, S., Jiayu, Z., & Sun, K. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1969017
“This gut–liver axis feedback is progressively impaired with MASLD-F (79), leading to reduced CYP7A1 expression and compromised cholesterol clearance.”
InfluentialQin, Z., Juramt, D., Chen, Y., Li, Y., Wei, J., Yang, H., Chen, L., & Qiu, W. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1946657
“Mechanistically, these alterations may reflect impaired FXR – FGF19 feedback, leading to insufficient suppression of CYP7A1-mediated bile acid synthesis, together with altered hepatocellular bile acid transport, including increased uptake and reduced canalicular efflux (101 – 103).”
Su, X., Li, X., Bian, Y., Li, L., Ren, Q., Liu, J., Luan, H., 李海天, Wu, X., Cheng, X., et al. (2026) · The Innovation Medicine · doi:10.59717/j.xinn-med.2026.100265 · Cited by 4
Zhang, Y., Chen, Y., Huang, S., Jiang, L., Wang, Y., Ma, J., Deng, R., Du, J., Xia, L., Ma, Y., et al. (2026) · medRxiv · doi:10.64898/2026.10.18.26365821
Metadata
- Authors
- Jiao, N., Baker, S. S., Chapa-Rodriguez, A., Liu, W., Nugent, C. A., Tsompana, M., Mastrandrea, L., Buck, M. J., Baker, R. D., Genco, R. J., Zhu, R., & Zhu, L.
- Affiliations
- Tongji University (CN)
- University at Buffalo, State University of New York (US)
- Department of Pediatrics, Digestive Diseases and Nutrition Center, The State University of New York at Buffalo, Buffalo, New York, USA
- Corresponding author
- Baker, Susan S
- Zhu, Lixin
- ORCID
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2017-08-03
- Volume
- 67
- Issue
- 10
- Pages
- 1881-1891
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2605955022
- Cited by
- 737
- References
- 50
- Citations by year
- 2026: 81 · 2025: 112 · 2024: 128 · 2023: 105 · 2022: 93 · 2021: 83 · 2020: 68 · 2019: 44 · 2018: 17 · 2017: 4
- FWCI
- 15.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Gut (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- GEM Community of Excellence, the University at Buffalo
- the University at Buffalo Departmental Start-Up Fund
- Natural Science Foundation of Shanghai
- National Natural Science Foundation of China
- the Peter and Tommy Fund, Inc., Buffalo, NY
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- non-alcoholic fatty liver disease, bile acids, bile acid signaling, farnesoid X receptor, FGFR4, FGF19, gut microbiota, secondary bile acids, deoxycholic acid, lithocholic acid, taurine metabolism, hepatic gene expression, high-fat diet
- MeSH terms
- Gastrointestinal Microbiome, Receptor, Farnesoid X-Activated, Animals, Bile Acids and Salts, Cholesterol 7-alpha-Hydroxylase, Female, Fibroblast Growth Factors, Humans, Male, Middle Aged, Signal Transduction, Receptors, Cytoplasmic and Nuclear, Gene Expression Profiling, Rats, Diet, High-Fat, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
